Skip to main content

Table 3 Baseline characteristics of 1095 colorectal cancer patients stratified by stage and tumor location

From: Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer

Characteristic

Stage I

Stage II

Stage III

Stage IV

 

Right-sided colon (%)

Left-sided colon (%)

P value

Right-sided colon (%)

Left-sided colon (%)

P value

Right-sided colon (%)

Left-sided colon (%)

P value

Right-sided colon (%)

Left-sided colon (%)

P value

N = 28 (14.6 %)

N = 164 (85.3 %)

N = 101 (26.1 %)

N = 286 (73.9 %)

N = 80 (24.2 %)

N = 251 (75.8 %)

N = 40 (21.4 %)

N = 145 (78.4 %)

Age (years, mean ± SD)

67.36 ± 10.05

65.04 ± 13.20

0.289

65.90 ± 13.67

65.30 ± 12.15

0.678

61.99 ± 14.86

61.90 ± 13.21

0.959

66.70 ± 11.57

62.85 ± 12.77

0.087

Gender

  

0.603

  

0.244

  

0.751

  

0.011*

 Female

12 (42.9)

79 (48.2)

52 (47.3)

128 (40.9)

37 (46.3)

111 (44.2)

23 (57.5)

51 (35.2)

 Male

16 (57.1)

85 (51.8)

58 (52.7)

185 (59.1)

43 (53.8)

140 (55.8)

17 (42.5)

94 (64.8)

Tumor size

  

1.000

  

0.060

  

0.070

  

0.921

  < 5 cm

24 (85.7)

139 (85.8)

42 (41.6)

150 (52.4)

37 (46.3)

144 (57.8)

18 (46.2)

62 (45.3)

  ≥ 5 cm

4 (14.3)

23 (14.2)

59 (58.4)

136 (47.6)

43 (53.8)

105 (42.2)

21 (53.8)

75 (54.7)

Histology

  

0.195

  

0.002*

  

0.036*

  

0.517

 Well

10 (35.7)

32 (20.3)

6 (6.1)

11 (3.9)

3 (3.9)

5 (2.0)

1 (2.6)

3 (2.2)

 Moderately

17 (60.7)

120 (75.9)

76 (76.8)

255 (90.1)

57 (74.0)

212 (86.5)

31 (79.5)

117 (86.7)

 Poorly

1 (3.6)

6 (3.8)

17 (17.2)

17 (6.0)

17 (22.1)

28 (11.4)

7 (17.9)

15 (11.1)

Tumor depth

  

0.872

  

0.197

  

0.457

  

0.858

 T1

10 (35.7)

56 (34.1)

0 (0.0)

0 (0.0)

2 (2.5)

2 (0.8)

0 (0.0)

1 (0.7)

 T2

18 (64.3)

108 (65.9)

0 (0.0)

0 (0.0)

5 (6.3)

25 (10.0)

1 (2.6)

6 (4.3)

 T3

0 (0.0)

0 (0.0)

101 (100.0)

279 (97.6)

67 (83.8)

209 (83.3)

31 (79.5)

103 (74.1)

 T4

0 (0.0)

0 (0.0)

0 (0.0)

7 (2.4)

6 (7.5)

15 (6.0)

7 (17.9)

29 (20.9)

Lymph Node metastasis

     

0.158

 

0.813

 N0

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

13 (33.3)

41 (30.1)

 N1

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

49 (61.3)

175 (69.7)

13 (33.3)

42 (30.9)

 N2

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

31 (38.8)

76 (30.3)

13 (33.3)

53 (39.0)

Vascular invasion

  

0.695

  

0.133

  

0.110

  

0.510

 No

27 (96.4)

146 (92.4)

83 (82.2)

211 (74.8)

39 (48.8)

145 (58.9)

14 (38.9)

59 (45.0)

 Yes

1 (3.6)

12 (7.6)

18 (17.8)

71 (25.2)

41 (51.2)

101 (41.1)

22 (61.1)

72 (55.0)

Perineural invasion

  

0.473

  

0.861

  

0.512

  

0.790

 No

27 (96.4)

143 (90.5)

67 (66.3)

185 (65.4)

47 (59.5)

136 (55.3)

16 (42.1)

52 (39.7)

 Yes

1 (3.6)

15 (9.5)

34 (33.7)

98 (34.6)

32 (40.5)

110 (44.7)

22 (57.9)

79 (60.3)

Pre-op serum CEAa level

  

0.560

  

0.237

  

0.043*

  

0.410

  < 5 ng/ml

22 (81.5)

127 (85.8)

62 (62.6)

150 (55.8)

28 (38.4)

122 (51.9)

9 (25.0)

25 (18.8)

  ≥ 5 ng/ml

5 (18.5)

21 (14.2)

37 (37.4)

119 (44.2)

45 (61.6)

113 (48.1)

27 (75.0)

108 (81.2)

 

Post-op serum CEAa level

  

0.697

  

0.158

  

0.025*

  

0.764

  < 5 ng/ml

24 (96.0)

140 (92.1)

75 (79.8)

232 (85.9)

49 (64.5)

185 (77.4)

10 (27.0)

37 (29.6)

  ≥ 5 ng/ml

1 (4.0)

12 (7.9)

19 (20.2)

38 (14.1)

27 (35.5)

54 (22.6)

27 (73.0)

88 (70.4)

Pre-op serum Albumin level (g/dl)

3.72 ± 0.37

3.76 ± 0.39

0.664

3.46 ± 0.47

3.58 ± 0.46

0.030

3.68 ± 0.37

3.69 ± 0.40

0.887

3.48 ± 0.45

3.46 ± 0.50

0.885

Diabetes mellitus

  

0.307

 

0.841

 

0.920

 

0.844

 Yes

9 (32.1)

38 (23.2)

24 (23.8)

69 (24.1)

19 (23.8)

61 (24.3)

8 (20.0)

27 (18.6)

 No

19 (67.9)

126 (76.8)

77 (76.2)

217 (75.9)

62 (76.2)

190 (75.7)

32 (80.0)

118 (81.4)

Chemotherapy

     

0.030*

  

0.852

  

0.817

 Yes

53 (52.5)

185 (64.7)

72 (91.1)

227 (90.4)

33(82.6)

121 (84.0)

 No

48 (47.5)

101 (35.3)

7 (8.9)

24 (9.6)

7 (17.5)

23 (16.0)

Cardiac disease

  

0.257

  

0.365

  

0.772

  

0.976

 Yes

15 (53.6)

69 (42.1)

41 (40.6)

131 (45.8)

32 (40.0)

105 (41.8)

15 (37.5)

54 (37.2)

 No

13 (46.4)

95 (57.9)

60 (59.4)

156 (54.2)

48 (60.0)

146 (58.2)

25 (62.5)

91 (62.8)

Renal disease

  

0.127*

  

0.693

  

0.450

  

1.000

 Yes

3 (10.7)

6 (3.7)

6 (5.9)

14 (4.9)

2 (2.5)

11 (4.4)

2 (5.0)

8 (5.5)

 No

25 (89.3)

158 (96.3)

95 (94.1)

272 (95.1)

78 (97.5)

240 (95.6)

38 (95.0)

137 (94.5)

BMIb

23.94 ± 3.88

23.70 ± 3.73

0.748

23.80 ± 4.39

23.73 ± 3.73

0.092

23.71 ± 4.13

23.95 ± 3.44

0.616

22.23 ± 4.31

22.77 ± 3.50

0.418

  1. aCEA Carcinoembryonic antigen, bBMI Body mass index, *Indicated P < 0.05